Mineralys Therapeutics, Inc.
Key Metrics
Market Snapshot
About
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and chronic kidney disease. The company's lead candidate, lorundrostat, is an aldosterone synthase inhibitor designed to lower blood pressure and reduce cardiovascular and renal risk. Mineralys targets patients with uncontrolled hypertension and cardiorenal conditions.